GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target cells at ...

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Oxford University is hoping to create a vaccine to stop the disease 20 years before it develops, as part of a joint project ...